within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DA05_Aminophylline;

model Aminophylline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 7.388888888888889e-07,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.00045,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aminophylline</td></tr><tr><td>ATC code:</td><td>R03DA05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.45</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.038</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aminophylline is a bronchodilator consisting of theophylline and ethylenediamine, used in the management of asthma, chronic obstructive pulmonary disease (COPD), and sometimes apnea of prematurity. It is administered orally or intravenously, though its use has declined due to the availability of newer agents. Aminophylline is still approved and used in certain clinical contexts.</p><h4>Pharmacokinetics</h4><p>PK parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Moore, ES, et al., &amp; Grasela, TH (1989). The population pharmacokinetics of theophylline in neonates and young infants. <i>Journal of pharmacokinetics and biopharmaceutics</i> 17(1) 47–66. DOI:<a href=\"https://doi.org/10.1007/BF01059087\">10.1007/BF01059087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2715932/\">https://pubmed.ncbi.nlm.nih.gov/2715932</a></p></li><li><p>Frymoyer, A, et al., &amp; Chock, VY (2020). Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. <i>Pediatric research</i> 88(6) 871–877. DOI:<a href=\"https://doi.org/10.1038/s41390-020-01140-8\">10.1038/s41390-020-01140-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32919393/\">https://pubmed.ncbi.nlm.nih.gov/32919393</a></p></li><li><p>Park, K, et al., &amp; Halstead, ES (2018). No Requirement for Targeted Theophylline Levels for Diuretic Effect of Aminophylline in Critically Ill Children. <i>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</i> 19(8) e425–e432. DOI:<a href=\"https://doi.org/10.1097/PCC.0000000000001608\">10.1097/PCC.0000000000001608</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29927879/\">https://pubmed.ncbi.nlm.nih.gov/29927879</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03DA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aminophylline;
